Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung.
Citation: Journal for Immunotherapy of Cancer. 9(2), 2021 02.PMID: 33597218Institution: MedStar Washington Hospital Center | Washington Cancer InstituteDepartment: Medicine/Internal MedicineForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: *Carcinoma, Large Cell/dt [Drug Therapy] | *Carcinoma, Neuroendocrine/dt [Drug Therapy] | *Immune Checkpoint Inhibitors/tu [Therapeutic Use] | *Lung Neoplasms/dt [Drug Therapy] | Aged | Carcinoma, Large Cell/im [Immunology] | Carcinoma, Large Cell/mo [Mortality] | Carcinoma, Large Cell/sc [Secondary] | Carcinoma, Neuroendocrine/im [Immunology] | Carcinoma, Neuroendocrine/mo [Mortality] | Carcinoma, Neuroendocrine/sc [Secondary] | District of Columbia | Female | Humans | Immune Checkpoint Inhibitors/ae [Adverse Effects] | Israel | Lung Neoplasms/im [Immunology] | Lung Neoplasms/mo [Mortality] | Lung Neoplasms/pa [Pathology] | Male | Middle Aged | Retrospective Studies | Risk Assessment | Risk Factors | Time Factors | Treatment Outcome | Tumor MicroenvironmentYear: 2021ISSN:- 2051-1426
- Kim, Chul:
- http://orcid.org/0000-0003-0191-8684
Item type | Current library | Collection | Call number | Status | Date due | Barcode |
---|---|---|---|---|---|---|
Journal Article | MedStar Authors Catalog | Article | 33597218 | Available | 33597218 |
BACKGROUND: Little is known regarding the efficacy of immune checkpoint inhibitors (ICI) in patients with advanced large-cell neuroendocrine lung carcinoma (aLCNEC).
CONCLUSIONS: With the limitations of retrospective design and small sample size, the results of this real-world cohort analysis suggest a positive impact of ICI on OS in aLCNEC. Copyright (c) Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
METHODS: 125 consecutive patients with aLCNEC were identified in the electronic databases of 4 participating cancer centers. The patients were divided into group A (patients who received ICI, n=41) and group B (patients who did not receive ICI, n=84). Overall survival since advanced disease diagnosis (OS DX) and OS since ICI initiation (OS ICI) were captured.
RESULTS: With a median follow-up of 11.8 months (mo) (IQR 7.5-17.9) and 6.0mo (IQR 3.1-10.9), 66% and 76% of patients died in groups A and B, respectively. Median OS DX was 12.4mo (95% CI 10.7 to 23.4) and 6.0mo (95% CI 4.7 to 9.4) in groups A and B, respectively (log-rank test, p=0.02). For ICI administration, HR for OS DX was 0.59 (95% CI 0.38 to 0.93, p=0.02-unadjusted), and 0.58 (95% CI 0.34 to 0.98, p=0.04-adjusted for age, Eastern Cooperative Oncology Group (ECOG) performance status (PS), presence of liver metastases and chemotherapy administration). In a propensity score matching analysis (n=74; 37 patients in each group matched for age and ECOG PS), median OS DX was 12.5 mo (95% CI 10.6 to 25.2) and 8.4 mo (95% CI 5.4 to 16.9) in matched groups A and B, respectively (log-rank test, p=0.046). OS ICI for patients receiving ICI as monotherapy (n=36) was 11.0 mo (95% CI 6.1 to 19.4).
English